Clinical Commander

Back to dossier
cardio.atrial_flutter.cocaine-related.v1PRODUCTION
cardio.atrial_flutter.cocaine-related.v1

Cocaine-induced atrial flutter (sympathetic + α-adrenergic + Na-channel substrate)

cardiologyacuteadult
Hard-required inputs
0 / 16
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm cocaine-related AFL per AHA 2008 PMID 18391116 — distinguish sympathetic-crisis-driven AFL vs concurrent ACS-induced AFL vs accelerated atrial-substrate AFL in chronic users; rule out aortic dissection FIRST (AHA 2008 mandatory before heparin or AC)

Inputs
2
Actions
0
Advance rule
Set
Advance when

cocaine etiology confirmed + dissection excluded

Patient inputs (18)

Cocaine-related AFL commoner age 25–55; younger than typical type-1 AFL substrate; informs differential weighting + bleed-risk balance

AFL with RVR HR 130–180+ typical; sinus tachycardia from sympathetic surge often coexists; QRS widening warns of Na-channel blockade requiring NaHCO3 (workup.cocaine_chest_pain)

Chronic users (Hsue 2002 PMID 12473532) have accelerated atrial substrate → higher recurrence + ablation candidacy; first-time use → reversible cause if cessation achieved

Alcohol → cocaethylene (more cardiotoxic + arrhythmogenic); benzo / opioid co-use changes sedation strategy + intentionality screen

Confirms cocaine / amphetamine exposure; benzoylecgonine detectable 2–4 d post-use; informs disposition + substance use disorder treatment referral

Troponin elevation common with cocaine — distinguishes concurrent ACS (cocaine-induced MI) from isolated AFL with demand ischemia from RVR; gates acs_pathway routing

Rhabdomyolysis common with cocaine + agitation → AKI; influences AC dosing + DOAC dose selection per KDIGO 2026

Rhabdomyolysis screen — common with cocaine + agitation + restraint; gates aggressive IVF

K+ ≥4 and Mg ≥2 mandatory before any DCCV or AAD; cocaine + diuretic effect or rhabdo can deplete

Confirm AFL morphology; rule out STEMI mimic (cocaine vasospasm); assess QRS width (Na-channel blockade) + QTc baseline before any AAD

Aortic dissection screen (mandatory in cocaine context per AHA 2008); pulmonary edema; PTX from valsalva or "crack lung"

Bedside echo: LVEF, valvular function, LA size, thrombus screen, pre-existing cocaine cardiomyopathy assessment in chronic users

Sympathetic crisis SBP often >180; gates phentolamine + nitroglycerin; hypotension + AFL = SCAI B-C cardiogenic-shock screen + emergent CV; rule out aortic dissection if discordant arm BPs (cocaine doubles dissection risk per IRAD)

Hyperthermia >39 + agitation = severe cocaine toxicity → aggressive cooling + benzodiazepine (NOT antipsychotic per AHA 2008)

AFL stroke risk identical to AF; in cocaine substrate counseling on AC adherence is critical given recidivism; LAA occlusion candidacy if persistent active use

HAS-BLED elevated in cocaine users (uncontrolled HTN + alcohol + polypharmacy + injection sites); AC bleed-risk balance

Reversible cause screen (thyrotoxic flutter); cocaine may unmask occult hyperthyroidism via sympathetic potentiation

CT-A chest if any concern for aortic dissection (cocaine doubles dissection risk per Eagle IRAD); MUST rule out before heparin or AC for AFL

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateningbeta_blocker_exposure_error_in_cocaine_user
    Inadvertent β-blocker (metoprolol, propranolol, atenolol, esmolol) administration to active cocaine user → unopposed-α paradox with worsening HTN, coronary vasospasm, potential ischemic event — Lange NEJM 1989 (PMID 2522592)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningconcurrent_MI_or_aortic_dissection_with_aflutter
    Cocaine-related AFL with concurrent troponin rise + ECG ischemic changes (MI suspected) OR severe chest/back pain + discordant arm BPs (aortic dissection suspected) — AHA 2008 mandatory rule-out before AC
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningsuicide_attempt_with_cocaine_co_ingestion
    Cocaine-related AFL in setting of intentional overdose with co-ingestion of TCA, opioid, alcohol, or other drugs — multi-drug toxidrome with high mortality
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_cocaine_use_with_aflutter_recurrence
    Documented recurrent cocaine use (positive UDS or self-report) within 30 days of discharge + AFL recurrence requiring ED/hospital readmission
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

Cocaine-induced atrial flutter — benzo first + diltiazem-preferred rate control + DCCV if unstable + standard AC + AVOID β-blocker monotherapy + cessation mandatory — AHA 2008 (PMID 18391116) + ACC/AHA 2024 (PMID 38753446) + ACC/AHA 2025 ACS
axis: cocaine_aflutter_phenotype
Selected axis "Cocaine-induced atrial flutter — benzo first + diltiazem-preferred rate control + DCCV if unstable + standard AC + AVOID β-blocker monotherapy + cessation mandatory — AHA 2008 (PMID 18391116) + ACC/AHA 2024 (PMID 38753446) + ACC/AHA 2025 ACS" by default fallback (first axis)
  • lorazepam
    first line
    benzodiazepine
    1–2 mg IV • IV • q5–15 min PRN sympathetic crisis
    triggers: cocaine_use_with_aflutter, sympathetic_crisis, agitation, hypertensive_emergency_pattern
    AHA 2008 Class I (PMID 18391116) — benzo breaks sympathetic crisis, reduces myocardial oxygen demand and BP, often reduces RVR through sympatholytic effect; first-line in cocaine arrhythmia
    rxcui 6470
  • nitroglycerin
    first line
    nitrate_vasodilator
    0.4 mg SL q5 min × 3 → IV 5–200 mcg/min if persistent HTN or chest pain • SL/IV • continuous IV titrate to BP and pain
    triggers: cocaine_with_HTN_crisis, concurrent_chest_pain_with_AFL, coronary_vasospasm_suspected
    AHA 2008 Class I — reverses cocaine-induced coronary vasoconstriction + reduces afterload; preferred over BB acutely
    rxcui 4917
  • phentolamine
    second line
    alpha_blocker_nonselective
    1–5 mg IV q5–15 min • IV • PRN refractory HTN
    triggers: refractory_HTN_after_benzo_and_NTG, severe_alpha_adrenergic_crisis, inadvertent_beta_blocker_exposure_with_cocaine
    AHA 2008 Class IIa — selective α-block reverses cocaine-induced vasoconstriction without unopposed-α paradox; reverses inadvertent BB-cocaine interaction (Lange NEJM 1989 PMID 2522592)
    rxcui 8153
  • diltiazem
    first line
    non_DHP_CCB
    0.25 mg/kg IV bolus → 5–15 mg/h infusion; 120–360 mg/day PO • IV/PO • IV bolus + infusion → PO daily
    triggers: cocaine_AFL_with_RVR_after_benzo, rate_control_first_line_in_cocaine_AFL
    AHA 2008 + ACC/AHA 2025 — non-DHP CCB PREFERRED over β-blocker in cocaine context (no unopposed-α paradox); AVN slowing for AFL rate control; AVOID in HFrEF or hypotension
    rxcui 3443
  • verapamil
    second line
    non_DHP_CCB
    5–10 mg IV slowly OR 80–120 mg PO TID • IV/PO • IV / PO
    triggers: diltiazem_intolerance, EF_normal
    Alternative non-DHP CCB; AVOID in HFrEF — AHA 2008 + ACC/AHA 2024 (PMID 38753446)
    rxcui 11170
  • synchronized_DCCV_100J_biphasic
    first line
    electrical_cardioversion
    100 J synchronized biphasic; escalate to 200 J if unsuccessful • electrical • single shock; may repeat at higher energy
    triggers: hemodynamic_instability_with_cocaine_aflutter, failed_pharmacologic_rate_control_with_decompensation
    ACC/AHA 2024 Class I (PMID 38753446); flutter cardioverts at low energies; first ensure cocaine-related hyperadrenergic state is treated to reduce post-CV recurrence + replete K + Mg
  • amiodarone
    second line
    class_III_AAD
    150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance • IV/PO • load + daily
    triggers: failed_rate_control_with_diltiazem_+_benzo, rhythm_strategy_in_chronic_cocaine_user_with_recurrent_AFL, structural_heart_disease_substrate
    Acceptable in cocaine context (no β-blocker paradox); minimal pure β-blockade effect; pulm/thyroid/hepatic toxicity with chronic use — ACC/AHA 2024 (PMID 38753446)
    rxcui 703
  • apixaban
    first line
    DOAC_factor_Xa
    5 mg BID (2.5 mg if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) • PO • BID
    triggers: CHA2DS2VASc_>=2_men_>=3_women, post_cardioversion_AC, long_term_AFL_AC
    ARISTOTLE (Granger NEJM 2011 PMID 21870978) — preferred DOAC; ACC/AHA 2024 Class I; counseling on adherence critical in cocaine substrate
    rxcui 1364430
  • rivaroxaban
    first line
    DOAC_factor_Xa
    20 mg with food (15 mg if CrCl 15–50) • PO • once daily
    triggers: apixaban_unavailable, once_daily_compliance_preference
    ROCKET-AF (PMID 21830957); X-VeRT data extends to flutter — ACC/AHA 2024
    rxcui 1114195
  • warfarin
    comorbidity specific
    vitamin_K_antagonist
    INR target 2–3 • PO • daily
    triggers: mechanical_valve, severe_mitral_stenosis, DOAC_contraindicated_or_intolerant, frequent_drug_interaction_concerns
    Mechanical valve / severe MS only; INR monitoring may be unreliable in non-adherent cocaine users — ACC/AHA 2024 (PMID 38753446)
    rxcui 11289

outpatient playbook — drug actions (3)

  1. 1. continue DOAC if AFL persistent
    rxcui 1364430
    apixaban 5 mg BID per dose-reduction criteria • PO • BID
    trigger: Persistent AFL post-cessation
    ACC/AHA 2024
  2. 2. continue diltiazem if needed
    rxcui 3443
    120–360 mg/day PO • PO • daily
    trigger: Rate control or recurrence prevention
    AHA 2008 + ACC/AHA 2024
  3. 3. consider β-blocker only if cocaine-free ≥1 month
    rxcui 20352
    carvedilol 3.125 mg BID titrate (mixed α/β preferred) • PO • BID
    trigger: Cocaine-free + HFrEF substrate
    AHA 2008 — pure β-blocker still avoided indefinitely if recurrent use

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Recent cocaine / sympathomimetic use (within 1–24 h) presenting with new atrial flutter on 12-lead ECG (AHA 2008 PMID 18391116); Atrial flutter on ECG + positive urine drug screen for cocaine / amphetamine metabolites (benzoylecgonine detectable 2–4 d post-use); Hypertension + tachycardia + agitation + diaphoresis + palpitations after cocaine use with AFL pattern — sympathomimetic α-adrenergic crisis with atrial arrhythmia.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cocaine-induced atrial flutter (sympathetic + α-adrenergic + Na-channel substrate)** (cardio.atrial_flutter.cocaine-related.v1).
Phenotype framing: Cocaine-induced AFL (acute sympathetic) vs cocaine-induced AFL with concurrent ACS vs cocaine-cardiomyopathy AFL (chronic substrate) vs aortic dissection presenting as palpitations vs thyrotoxic flutter unmasked by cocaine
Scope: Confirm cocaine-related AFL per AHA 2008 PMID 18391116 — distinguish sympathetic-crisis-driven AFL vs concurrent ACS-induced AFL vs accelerated atrial-substrate AFL in chronic users; rule out aortic dissection FIRST (AHA 2008 mandatory before heparin or AC)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Cocaine-induced atrial flutter — benzo first + diltiazem-preferred rate control + DCCV if unstable + standard AC + AVOID β-blocker monotherapy + cessation mandatory — AHA 2008 (PMID 18391116) + ACC/AHA 2024 (PMID 38753446) + ACC/AHA 2025 ACS**.
1. lorazepam 1–2 mg IV IV q5–15 min PRN sympathetic crisis (benzodiazepine, first line) — AHA 2008 Class I (PMID 18391116) — benzo breaks sympathetic crisis, reduces myocardial oxygen demand and BP, often reduces RVR through sympatholytic effect; first-line in cocaine arrhythmia
2. nitroglycerin 0.4 mg SL q5 min × 3 → IV 5–200 mcg/min if persistent HTN or chest pain SL/IV continuous IV titrate to BP and pain (nitrate_vasodilator, first line) — AHA 2008 Class I — reverses cocaine-induced coronary vasoconstriction + reduces afterload; preferred over BB acutely
3. phentolamine 1–5 mg IV q5–15 min IV PRN refractory HTN (alpha_blocker_nonselective, second line) — AHA 2008 Class IIa — selective α-block reverses cocaine-induced vasoconstriction without unopposed-α paradox; reverses inadvertent BB-cocaine interaction (Lange NEJM 1989 PMID 2522592)
4. diltiazem 0.25 mg/kg IV bolus → 5–15 mg/h infusion; 120–360 mg/day PO IV/PO IV bolus + infusion → PO daily (non_DHP_CCB, first line) — AHA 2008 + ACC/AHA 2025 — non-DHP CCB PREFERRED over β-blocker in cocaine context (no unopposed-α paradox); AVN slowing for AFL rate control; AVOID in HFrEF or hypotension
5. verapamil 5–10 mg IV slowly OR 80–120 mg PO TID IV/PO IV / PO (non_DHP_CCB, second line) — Alternative non-DHP CCB; AVOID in HFrEF — AHA 2008 + ACC/AHA 2024 (PMID 38753446)
6. synchronized_DCCV_100J_biphasic 100 J synchronized biphasic; escalate to 200 J if unsuccessful electrical single shock; may repeat at higher energy (electrical_cardioversion, first line) — ACC/AHA 2024 Class I (PMID 38753446); flutter cardioverts at low energies; first ensure cocaine-related hyperadrenergic state is treated to reduce post-CV recurrence + replete K + Mg
7. amiodarone 150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance IV/PO load + daily (class_III_AAD, second line) — Acceptable in cocaine context (no β-blocker paradox); minimal pure β-blockade effect; pulm/thyroid/hepatic toxicity with chronic use — ACC/AHA 2024 (PMID 38753446)
8. apixaban 5 mg BID (2.5 mg if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) PO BID (DOAC_factor_Xa, first line) — ARISTOTLE (Granger NEJM 2011 PMID 21870978) — preferred DOAC; ACC/AHA 2024 Class I; counseling on adherence critical in cocaine substrate
9. rivaroxaban 20 mg with food (15 mg if CrCl 15–50) PO once daily (DOAC_factor_Xa, first line) — ROCKET-AF (PMID 21830957); X-VeRT data extends to flutter — ACC/AHA 2024
10. warfarin INR target 2–3 PO daily (vitamin_K_antagonist, comorbidity specific) — Mechanical valve / severe MS only; INR monitoring may be unreliable in non-adherent cocaine users — ACC/AHA 2024 (PMID 38753446)

Setting playbook (outpatient) — Long-term AFL + substance use disorder management: lifelong DOAC if AFL persistent + post-cessation, post-ablation surveillance, addiction medicine continuity, primary prevention of recurrence — ACC/AHA 2024 + AHA 2008
11. continue DOAC if AFL persistent apixaban 5 mg BID per dose-reduction criteria PO BID — Persistent AFL post-cessation (ACC/AHA 2024)
12. continue diltiazem if needed 120–360 mg/day PO PO daily — Rate control or recurrence prevention (AHA 2008 + ACC/AHA 2024)
13. consider β-blocker only if cocaine-free ≥1 month carvedilol 3.125 mg BID titrate (mixed α/β preferred) PO BID — Cocaine-free + HFrEF substrate (AHA 2008 — pure β-blocker still avoided indefinitely if recurrent use)

Non-pharmacologic actions:
- Addiction medicine continuity — long-term peer support, MAT, behavioral therapy
- CTI ablation if recurrent typical AFL — Calkins 2007 (PMID 17572388)
- LAA occlusion (Watchman) if AC contraindicated long-term due to active use bleed risk — ACC/AHA 2024
- Cardiac rehab maintenance phase
- Lifestyle: BP, weight, alcohol cessation, OSA

AVOID / contraindication checks:
- Beta_blocker_monotherapy_AVOID_in_acute_or_active_cocaine_use (ACC/AHA 2025 ACS Class III; AHA 2008 PMID 18391116; Lange NEJM 1989 PMID 2522592)
- Flecainide_propafenone_AVOID_in_cocaine_AFL (additive Na channel blockade; QRS prolongation; structural heart disease cocaine induced cardiomyopathy substrate per CAST PMID 1900101)
- Full_dose_diltiazem_AVOID_if_HFrEF_or_SBP_below_100 (AHA 2008 + ACC/AHA 2024 PMID 38753446)
- Digoxin_AVOID_with_WPW_or_active_cocaine_use_due_to_proarrhythmia_risk (ACC/AHA 2024)
- Do_not_anticoagulate_until_aortic_dissection_excluded (cocaine doubles dissection risk per IRAD; AHA 2008 PMID 18391116)
- K_must_be_>=4_and_Mg_must_be_>=2_pre_DCCV_or_AAD (ACC/AHA 2024)
- Procainamide_AVOID_in_cocaine_VT_VF (Na block additive)
- Carvedilol_or_metoprolol_DEFER_until_cocaine_free_>=1_week (AHA 2008 — mixed α/β agent acceptable later)

Monitoring

Regimen monitoring:
- continuous telemetry for AFL and post treatment arrhythmia — AHA 2008
- BP q15min until <160 then q1h — AHA 2008
- serial ECG q15min x 1h for QRS widening progression or resolution — AHA 2008
- CPK q6h x 24h if rhabdo present — KDIGO 2026
- daily K Mg BMP — ACC/AHA 2024
- QTc daily on amiodarone or class III — ACC/AHA 2024
- 4-week post CV AC continuation regardless of CHA2DS2 VASc — ACC/AHA 2024 Class I
- lifelong AC per CHA2DS2 VASc if AFL persistent — ACC/AHA 2024
- cocaine cessation counseling documented at each visit — Hollander NEJM 2008

Setting (outpatient) monitoring:
- Quarterly clinic + annual echo
- CBC + eGFR q6m on DOAC
- Holter at 6 + 12 mo post-ablation
- UDS per addiction medicine

Follow-up plan: COCAINE CESSATION counseling MANDATORY + warm handoff to substance use disorder treatment (mortality lever per Hollander NEJM 2008); cardiology follow-up week 1 + month 1; EP for CTI ablation if recurrent typical AFL; cardiac rehab; AC adherence review + LAA occlusion candidacy if persistent active use; AVOID β-blocker initiation if continued cocaine use — use diltiazem or non-pharmacologic rate control instead
- Close-out criterion: substance use disorder referral + cardiology follow-up booked + AC plan with adherence support

Monitoring phase: Continuous ECG; repeat troponin to peak if elevated; BP q15 min until <160; CPK q6 h × 24 h if rhabdo; bleed signs per BARC 2011; QTc daily on AAD; sedation cadence titration

Disposition

Current setting: outpatient — Long-term AFL + substance use disorder management: lifelong DOAC if AFL persistent + post-cessation, post-ablation surveillance, addiction medicine continuity, primary prevention of recurrence — ACC/AHA 2024 + AHA 2008

Disposition criteria:
- Continue chronic surveillance; cross-link to cardio.atrial_flutter.typical-cavotricuspid.v1 if typical morphology + ablation pathway

Escalation triggers (move to higher acuity):
- Cocaine relapse with arrhythmia → ED + addiction medicine urgent
- AC bleed → reverse + LAA occlusion candidacy reassessment
- Worsening cocaine cardiomyopathy → advanced HF / transplant evaluation (with strict cocaine-free requirement)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Inadvertent β-blocker (metoprolol, propranolol, atenolol, esmolol) administration to active cocaine user → unopposed-α paradox with worsening HTN, coronary vasospasm, potential ischemic event — Lange NEJM 1989 (PMID 2522592)
- [LIFE_THREATENING] Cocaine-related AFL with concurrent troponin rise + ECG ischemic changes (MI suspected) OR severe chest/back pain + discordant arm BPs (aortic dissection suspected) — AHA 2008 mandatory rule-out before AC
- [LIFE_THREATENING] Cocaine-related AFL in setting of intentional overdose with co-ingestion of TCA, opioid, alcohol, or other drugs — multi-drug toxidrome with high mortality

Citations

- 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + AHA 2008 Cocaine cardiovascular complications (McCord PMID 18391116) + 2025 ACC/AHA ACS Guideline [PMID:38753446](https://pubmed.ncbi.nlm.nih.gov/38753446/)
- Cited evidence (PMID 39050851) [PMID:39050851](https://pubmed.ncbi.nlm.nih.gov/39050851/)
- Cited evidence (PMID 18391116) [PMID:18391116](https://pubmed.ncbi.nlm.nih.gov/18391116/)
- Cited evidence (PMID 2522592) [PMID:2522592](https://pubmed.ncbi.nlm.nih.gov/2522592/)
- Cited evidence (PMID 34669377) [PMID:34669377](https://pubmed.ncbi.nlm.nih.gov/34669377/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + AHA 2008 Cocaine cardiovascular complications (McCord PMID 18391116) + 2025 ACC/AHA ACS Guideline — PMID:38753446
  • Cited evidence (PMID 39050851) — PMID:39050851
  • Cited evidence (PMID 18391116) — PMID:18391116
  • Cited evidence (PMID 2522592) — PMID:2522592
  • Cited evidence (PMID 34669377) — PMID:34669377